Roth Capital Confident in Full Sarilumab Approval; Affirms Regeneron (REGN) at 'Buy'
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Roth Capital affirms Regeneron Pharma (Nasdaq: REGN) at Buy with a price target of $520 following news that the company and Sanofi received an FDA complete response letter for Sarilumab. Sanofi has sent a "comprehensive action plan" to the FDA and will work for a timely resolution.
Analyst Joseph Pantginis commented:
As we stated earlier [Friday], we believe this is a modest perception hit but we expect full eventual approval of sarilumab for RA as the CRL does not address any safety or efficacy issues. REGN and Sanofi are working closely and quickly with the FDA to address the problems as they have already submitted to the FDA and started implementing a comprehensive correction plan which we believe will be keep the delay in approval to a minimum. While this may drive some near-term negative perception, both sarilumab and dupilumab should represent new revenue drivers for REGN. Additionally, the company has the ability, in our belief, to driver long-term pipeline growth.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Galena Biopharma (GALE) PT Raised to $4 at Maxim Group into San Antonio Breast Cancer Symposium
- Roth Capital Cuts PT on Heat Biologics (HTBX) by ~27% Following HS-410 Phase 2 Data
- JPMorgan Raises Rating on CBOE Holdings (CBOE) to 'Overweight'; Analyst Thinks Bats Technology Will Drive Greater Trading Activity
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Related EntitiesRoth Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!